Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review

Jurgen Sota, Donato Rigante, Giuseppe Lopalco, Bruno Frediani, Rossella Franceschini, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Claudia Fabiani, Luca Cantarini

Research output: Contribution to journalReview article

Abstract

Intraocular inflammation is one of the more relevant complications of Behçet’s disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.

Original languageEnglish
Pages (from-to)25-35
Number of pages11
JournalRheumatology International
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

    Fingerprint

Keywords

  • Behçet’s disease
  • Biologics
  • Eye disease
  • Treatment
  • Uveitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Sota, J., Rigante, D., Lopalco, G., Frediani, B., Franceschini, R., Galeazzi, M., Iannone, F., Tosi, G. M., Fabiani, C., & Cantarini, L. (2018). Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatology International, 38(1), 25-35. https://doi.org/10.1007/s00296-017-3775-5